menu
    • menu
    [{"orgOrder":0,"company":"CicloMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fosciclopirox","moa":"Cell membrane synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CicloMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CicloMed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CicloMed \/ Undisclosed"},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Fosciclopirox","moa":"||Cell membrane synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"7","companyTruncated":"Notable Labs \/ CicloMed LLC"},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fosciclopirox","moa":"Cell membrane synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ CicloMed LLC"},{"orgOrder":0,"company":"CicloMed","sponsor":"Cmed Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fosciclopirox","moa":"Cell membrane synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"CicloMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CicloMed \/ Cmed Clinical Services","highestDevelopmentStatusID":"6","companyTruncated":"CicloMed \/ Cmed Clinical Services"}]

    Find Clinical Drug Pipeline Developments & Deals for Fosciclopirox

    Menu

    Fosciclopirox

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Notable Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosciclopirox

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : CicloMed LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome

                            Details : CPX-POM (fosciclopirox) is a patented, parentally administered prodrug of a commercially available topical antifungal agent, ciclopirox. It is under phase 1/2 clinical development for the treatment of bladder cancer and Acute Myeloid Leukemia (AML).

                            Product Name : CPX-POM

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 18, 2023

                            Lead Product(s) : Fosciclopirox

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : CicloMed LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Notable Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosciclopirox,Cytarabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : CicloMed LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under ...

                            Details : Under the terms of co-development agreement, CicloMed holds the responsibility for executing clinical trial operations while Notable is focused on optimizing Notable’s predictive precision medicine platform with the goal of assessing patient responsive...

                            Product Name : CPX-POM

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 01, 2021

                            Lead Product(s) : Fosciclopirox,Cytarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CicloMed LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CicloMed

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CicloMed

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosciclopirox

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia

                            Details : Fosciclopirox is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 09, 2021

                            Lead Product(s) : Fosciclopirox

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CicloMed

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CicloMed

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosciclopirox

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cmed Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Soli...

                            Details : Fosciclopirox is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 21, 2017

                            Lead Product(s) : Fosciclopirox

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cmed Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth